The Benefits of Preserving Adaptive Immunity in Generalized Myasthenia Gravis (gMG) Patients

Key Takeaways:

• Both FcRn antagonists and complement inhibitors provide symptomatic control without the systemic lymphopenia or broad immunosuppression seen with traditional immunosuppressive therapies (ISTs).
• These targeted biologics spare the cellular adaptive immune system (T and B cells), maintaining these important host defenses.
• By minimizing the "immunological footprint," these therapies facilitate corticosteroid tapering and demonstrate safety profiles comparable to other immunosuppressives in trials.

The therapeutic landscape for generalized myasthenia gravis (gMG) has undergone a transformative shift with the advent of targeted biologics. While conventional immunosuppressive therapies (ISTs) have long served as the cornerstone of management, their non-specific nature – characterized by broad systemic immune suppression – often precipitates a precarious trade-off between disease control and host defense.¹

In recent years, the clinical focus has pivoted toward targeted immunomodulation – specifically through complement inhibitors and neonatal Fc receptor (FcRn) antagonists. These therapies represent a significant advancement: the ability to neutralize the pathogenic mechanisms of gMG while largely preserving the host’s adaptive immunity.^1,2

The problem with broad immunosuppression

Traditional ISTs generally function by inhibiting the proliferation of T and B lymphocytes or altering gene expression to suppress cytokine production. This broad immunosuppressive approach comes with a high clinical "tax." Traditional cytotoxic ISTs can increase the risk of opportunistic infections and secondary malignancies due to the sustained depletion of the adaptive immune repertoire.¹

For clinicians, the challenge is achieving "minimal manifestation status" without leaving the patient immunologically vulnerable.

FcRn antagonists: Targeted IgG clearance

The introduction of FcRn antagonists has revolutionized the management of IgG-mediated autoimmunity. These agents work by binding to the FcRn receptor, which is responsible for "recycling" IgG antibodies and preventing their lysosomal degradation. By blocking this pathway, these therapies accelerate the catabolism of all IgG subclasses, including the pathogenic anti-AChR and anti-MuSK antibodies.^1,2

Critically, FcRn antagonists do not affect the production of antibodies nor the viability of B or T lymphocytes. Unlike B-cell depleting therapies, the cells of the adaptive immune system remain intact.^1,2

Clinical data from the ADAPT+ long-term extension study of Efgartigimod, an FcRn antagonist, demonstrate that while total IgG levels are significantly reduced, levels of IgA and IgM – vital for mucosal immunity and initial pathogen recognition – remain relatively stable. This selectivity allows for a rapid reduction in disease burden while maintaining the patient’s ability to mount a cellular immune response to new antigens or vaccinations.³

Complement inhibitors: Selective effector blockade

In anti-AChR-positive gMG, the membrane attack complex (MAC) is the primary driver of postsynaptic membrane destruction. Terminal complement inhibitors specifically target the complement protein C5. By preventing the cleavage of C5 into C5a and C5b, these agents arrest the formation of the MAC (C5b-9) and mitigate the inflammatory signaling that recruits destructive immune cells to the neuromuscular junction.^4,5

From a preservation standpoint, C5 inhibition is strategically narrow. It leaves the "proximal" complement pathway (C1 - C4) intact. This is essential because proximal components like C3b are required for opsonization – the "tagging" of bacteria for clearance by phagocytes – and for the clearance of immune complexes. By sparing the proximal pathway and having no direct inhibitory effect on T or B cell proliferation or activation, C5 inhibitors treat the "effector" phase of the disease, directly interfering with the adaptive immune system.^4,5

Navigating the risk profile: Selective vs. systemic

While these targeted therapies are "less broad" than traditional ISTs, they are not without specific risks. The most notable for complement inhibitors is the increased vulnerability to encapsulated bacteria, specifically Neisseria meningitidis, requiring mandatory vaccination and vigilance.^5-7

Similarly, FcRn antagonists are associated with a higher incidence of upper respiratory tract infections and urinary tract infections, likely due to the temporary reduction in circulating IgG.^5,6

However, a 2026 retrospective longitudinal cohort study highlighted that ravulizumab-treated patients showed lower overall infection rates compared to those on broad B-cell depleting agents. This suggests that the "precision" of targeting the terminal complement pathway or IgG recycling may offer a more favorable long-term safety profile than the systemic "reset" required by older cytotoxic therapies.⁷

Moving toward precision

There is significant clinical benefit to preserving adaptive immunity in gMG patients. By using FcRn antagonists and complement inhibitors, clinicians can now more specifically target the pathophysiology of the disease – IgG-mediated damage and MAC-driven destruction – while sparing the patient's broader immunological defenses. This approach reduces the "collateral damage" seen with chronic steroid and broad IST use, potentially leading to better long-term safety outcomes and a higher quality of life.^1-5

As we move ahead, the integration of these targeted therapies is no longer just an alternative for refractory cases; it is becoming the cornerstone of a more precise, more immune-sparing strategy for all gMG patients.